Compare iShares Russell 2000 ETF (IWM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Russell 2000 ETF vs GeneDx Holdings Corp — how do they compare? iShares Russell 2000 ETF trades at $279.5 (market cap $77.70B), while GeneDx Holdings Corp trades at $67.71 (market cap $2.02B). The key difference: iShares Russell 2000 ETF is far larger — about 38.5× GeneDx Holdings Corp's market cap, and iShares Russell 2000 ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and GeneDx Holdings Corp for 19 Days on average.
| IWM | WGS | |
|---|---|---|
Market Cap | $77.70B | $2.02B |
Volume | 35,598,983 | 734,640 |
52-Week High | $305.06 | $167.51 |
52-Week Low | $229.13 | $34.51 |
Typical Hold Time | 83 Days | 19 Days |
Sector | — | Health |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $279.1, up 0.5% on the day. Technical indicators are predominantly bearish, with moving averages and ADX signaling a downtrend, though oscillators like RSI are neutral. The fund lacks traditional valuation ratios as it is an ETF, and recent news highlights its underperformance versus the S&P 500 over the past decade, with concerns about its inclusion of unprofitable companies.
The outlook for IWM is clouded by persistent underperformance and sensitivity to interest rate hikes, which pressure small caps. While offering diversification away from large-cap tech, the fund faces headwinds from economic tightening and narrow market breadth. A rebound hinges on broader market participation and favorable macroeconomic conditions, but near-term risks remain elevated.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Russell 2000 ETF
The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
